SCHEMBL483645

SCHEMBL483645

CCCCc1nc2c(N)nc3ccccc3c2n1CCCCCS(C)(=O)=O

nearest known ligand 0.76

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 20/20 0.76
TLR8 Q9NR97 3/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31006040 1.00 TLR7 (0.76) TLR7TLR8
SCHEMBL5360565 0.99 TLR7 (0.77) TLR7TLR8
SCHEMBL5354054 0.97 TLR7 (0.71) TLR7TLR8
SCHEMBL544952 0.96 TLR7 (0.75) TLR7TLR8
SCHEMBL29374474 0.96 TLR7 (0.75) TLR7TLR8
SCHEMBL5353504 0.95 TLR7 (0.67) TLR7TLR8
SCHEMBL3520339 0.94 TLR7 (0.76) TLR7TLR8
SCHEMBL5358579 0.94 TLR7 (0.69) TLR7TLR8
SCHEMBL5354224 0.93 TLR7 (0.74) TLR7TLR8
SCHEMBL5354768 0.92 TLR7 (0.76) TLR7TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7288550-B2 Thioether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-10-30 US claimed
US-20050209267-A1 Thioether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2005-09-22 US claimed
US-6921826-B2 Thioether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES CO. (US) 2005-07-26 US claimed
EP-1541572-A1 Thioether substituted imidazoquinolines 3M Innovative Properties Company (US) 2005-06-15 EP claimed
EP-1341791-B1 THIOETHER SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES CO (US) 2005-05-25 EP claimed
US-20040102471-A1 Thioether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2004-05-27 US claimed
US-20040097736-A1 Thioether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2004-05-20 US claimed
US-6664264-B2 Thioether substituted imidazoquinoline or tetrahydroimdazoquinoline compounds induce the biosynthesis of cytokines such as interferon and useful for treating viral disease in an animal 3M INNOVATIVE PROPERTIES COMPANY 2003-12-16 US claimed
EP-1341791-A2 THIOETHER SUBSTITUTED IMIDAZOQUINOLINES 3M Innovative Properties Company (US) 2003-09-10 EP claimed
US-20030100764-A1 Thioether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2003-05-29 US claimed
US-20020173655-A1 Thioether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2002-11-21 US claimed
WO-2002046192-A2 THIOETHER SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-06-13 WO claimed
US-20250152703-A1 COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2025-05-15 US disclosed
US-12201684-B2 Compositions for stimulation of mammalian innate immune resistance to pathogens THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-01-21 US disclosed
US-20240417738-A1 IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER OHIO STATE INNOVATION FOUNDATION 2024-12-19 US disclosed
US-11826422-B2 Methods and compositions for adaptive immune modulation BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-11-28 US disclosed
WO-2003050121-A1 THIOETHER SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-06-19 WO disclosed
US-20030100764-A1 Thioether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2003-05-29 US disclosed
US-20020173655-A1 Thioether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2002-11-21 US disclosed
WO-2002046192-A2 THIOETHER SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209267-A1 Thioether substituted imidazoquinolines IFNG, IRF3, IL2 TLR7 30/4885TLR8 107/4885
US-20040097736-A1 Thioether substituted imidazoquinolines IFNG, IRF3, IL2 TLR7 30/4885TLR8 107/4885
US-20020173655-A1 Thioether substituted imidazoquinolines IFNG, IRF3, IL2 TLR7 30/4885TLR8 107/4885
US-20040102471-A1 Thioether substituted imidazoquinolines IFNG, IRF3, IL2 TLR7 30/4885TLR8 107/4885
US-20030100764-A1 Thioether substituted imidazoquinolines IFNG, IRF3, IL2 TLR7 30/4885TLR8 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.